{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:51:33Z","timestamp":1795024293917,"version":"4.10.2"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T00:00:00Z","timestamp":1654387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>While direct\u2010acting antivirals (DAAs) cure chronic hepatitis C virus (HCV) infection in almost all patients, some patients remain at risk of liver disease despite HCV cure. In order to identify risk factors indicating liver\u2010related morbidity and death after viral cure, we included 6982 patients from the national multicenter real\u2010world German Hepatitis C Registry with regular follow\u2010up visits for up to 7\u2009years after DAA therapy. Definitions for normal liver function tests (in women\/men) were alanine aminotransferase (ALT; \u226435\/\u226450\u2009U\/L), ALT according to American Association for the Study of Liver Diseases (AASLD; \u226419\/\u226430\u2009U\/L), and gamma\u2010glutamyltransferase (GGT; \u226440\/\u226460\u2009U\/L). In our cohort, 97.4% of patients achieved sustained virologic response (SVR). At 24\u2009weeks after SVR (SVR24), elevated ALT occurred in 657\/6982 (9.4%), elevated ALT (AASLD) in 2609\/6982 (37.4%), and elevated GGT in 1777\/6982 (25.5%) patients. Risk factors for increased ALT at SVR24 were obesity, alcohol, cirrhosis, elevated baseline ALT, and non\u2010SVR. Increased GGT at SVR24 was significantly (<jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0&lt;\u20090.05) and independently associated with male sex (odds ratio [OR], 2.12), higher body mass index (OR, 1.04), age\u2009&gt;50\u2009years (OR, 1.60), liver cirrhosis (OR, 3.97), alcohol consumption (OR, 2.99), diabetes (OR, 1.63), non\u2010SVR (OR, 8.00), and elevated GGT at baseline (OR, 17.12). In multivariate regression analysis, elevated GGT at SVR24, particularly in combination with cirrhosis, was the best predictor for hepatic decompensation, hepatocellular carcinoma development, and death, followed by elevated ALT (AASLD) and standard ALT, which predicted hepatic decompensation. Despite successful HCV therapy, elevated GGT at SVR24 and to a lesser extent ALT are predictive of the future clinical outcome and linked with liver\u2010associated comorbidities. This may highlight the relevance of nonalcoholic fatty liver disease, diabetes mellitus, alcohol, and cirrhosis for the clinical outcome in a vulnerable population, even after HCV cure.<\/jats:p>","DOI":"10.1002\/hep4.2015","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T19:10:14Z","timestamp":1654456214000},"page":"2488-2495","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C\u2010Registry"],"prefix":"10.1097","volume":"6","author":[{"given":"Frank","family":"Tacke","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology,Charit\u00e9 \u2010 Universit\u00e4tsmedizin Berlin,Campus Virchow\u2010Klinikum and Campus Charit\u00e9 Mitte,Berlin,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg,W\u00fcrzburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H. W.","family":"Boeker","sequence":"additional","affiliation":[{"name":"Center of Hepatology,Hannover,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Merle","sequence":"additional","affiliation":[{"name":"Heidelberg University Hospital,Heidelberg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Link","sequence":"additional","affiliation":[{"name":"MVZ\u2010Offenburg GmbH\/St. Josefs\u2010Klinik,Offenburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[{"name":"ifi\u2010Institute for Interdisciplinary Medicine,Hamburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"H\u00fcppe","sequence":"additional","affiliation":[{"name":"Gastroenterologische Gemeinschaftspraxis Herne,Herne,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[{"name":"Hannover Medical School,Hannover,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[{"name":"St. Josefs\u2010Hospital,Wiesbaden,Germany"},{"name":"Goethe University Hospital,Frankfurt,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Hannover Medical School,Hannover,Germany"},{"name":"Leberstiftungs\u2010GmbH Deutschland,Hannover,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[{"name":"Leipzig University Medical Center,Leipzig,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Mauss","sequence":"additional","affiliation":[{"name":"Center for HIV and Hepatogastroenterology,D\u00fcsseldorf,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DHC\u2010R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,5]]},"reference":[{"key":"hep42015-bib-0001-20241118","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep42015-bib-0002-20241118","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3851\/IMP3186","article-title":"Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis","volume":"23","year":"2018","journal-title":"Antivir Ther"},{"key":"hep42015-bib-0003-20241118","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","article-title":"Hepatic benefits of HCV cure","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"hep42015-bib-0004-20241118","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2021.05.028","article-title":"Impact of direct\u2010acting antivirals for HCV on mortality in a large population\u2010based cohort study","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"hep42015-bib-0005-20241118","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2020.11.040","article-title":"Residual risk of liver disease after hepatitis C virus eradication","volume":"74","year":"2021","journal-title":"J Hepatol"},{"key":"hep42015-bib-0006-20241118","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","article-title":"Fatty liver in hepatitis C patients post\u2010sustained virological response with direct\u2010acting antivirals","volume":"24","year":"2018","journal-title":"World J Gastroenterol"},{"key":"hep42015-bib-0007-20241118","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep42015-bib-0008-20241118","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis\u2010related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep42015-bib-0009-20241118","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV\u2010related cirrhosis depend on disease severity","volume":"74","year":"2021","journal-title":"J Hepatol"},{"key":"hep42015-bib-0010-20241118","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non\u2010invasive tests accurately stratify patients with NAFLD based on their risk of liver\u2010related events","volume":"76","year":"2022","journal-title":"J Hepatol"},{"key":"hep42015-bib-0011-20241118","article-title":"Risk for hepatic and extra\u2010hepatic outcomes in nonalcoholic fatty liver disease","year":"2021","journal-title":"J Intern Med"},{"key":"hep42015-bib-0012-20241118","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy\u2010confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","year":"2021","journal-title":"Gut"},{"key":"hep42015-bib-0013-20241118","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/a-0752-0514","article-title":"Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C","volume":"57","year":"2019","journal-title":"Z Gastroenterol"},{"key":"hep42015-bib-0014-20241118","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/liv.14186","article-title":"Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs","volume":"40","year":"2020","journal-title":"Liver Int"},{"key":"hep42015-bib-0015-20241118","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/liv.13206","article-title":"Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials","volume":"37","year":"2017","journal-title":"Liver Int"},{"key":"hep42015-bib-0016-20241118","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"hep42015-bib-0017-20241118","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep42015-bib-0018-20241118","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2050640617716607","article-title":"Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real\u2010world setting","volume":"6","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"hep42015-bib-0019-20241118","first-page":"27","article-title":"4\u2009years of direct\u2010acting antivirals (DAAs) in the German Hepatitis C\u2010Registry (DHC\u2010R)","volume":"57","year":"2019","journal-title":"Z Gastroenterol"},{"key":"hep42015-bib-0020-20241118","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"hep42015-bib-0021-20241118","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/gut.2009.192732","article-title":"Abnormalities of lipid metabolism in hepatitis C virus infection","volume":"59","year":"2010","journal-title":"Gut"},{"key":"hep42015-bib-0022-20241118","doi-asserted-by":"crossref","first-page":"33466","DOI":"10.1074\/jbc.M109.019810","article-title":"Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice","volume":"284","year":"2009","journal-title":"J Biol Chem"},{"key":"hep42015-bib-0023-20241118","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0168-8278(00)00036-2","article-title":"Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C","volume":"34","year":"2001","journal-title":"J Hepatol"},{"key":"hep42015-bib-0024-20241118","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10620-005-2788-1","article-title":"Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver","volume":"50","year":"2005","journal-title":"Dig Dis Sci"},{"key":"hep42015-bib-0025-20241118","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","year":"2018","journal-title":"Gut"},{"key":"hep42015-bib-0026-20241118","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non\u2010invasive tests for evaluation of liver disease severity and prognosis \u2010 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.2015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.2015","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T12:01:26Z","timestamp":1731931286000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,5]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.2015","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,5]]},"assertion":[{"value":"2022-02-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}